Yoshihiko Fujita - Publications

MicroRNA-responsive ON-OFF hybrid mRNA switch for precise protein expression control.

Journal: Molecular therapy. Nucleic acids

Published: December 05, 2024

Exploration of genes related to the development of cancer of unknown primary.

Journal: Oncology reports

Published: November 19, 2024

Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.

Journal: Molecular and clinical oncology

Published: September 03, 2024

Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: March 22, 2023

Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain.

Journal: Oncology letters

Published: March 16, 2023

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study).

Journal: The oncologist

Published: June 22, 2022

Translational recoding by chemical modification of non-AUG start codon ribonucleotide bases.

Journal: Science advances

Published: April 08, 2022

Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: February 10, 2022

A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches.

Journal: Science advances

Published: January 05, 2022

Influences of remote exercise training for community-dwelling older adults in Japan during the COVID-19 pandemic.

Journal: Journal of physical therapy science

Published: June 24, 2021

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.

Journal: JAMA oncology

Published: October 15, 2020

PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: October 14, 2020